NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05668585 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors Status COMPLETED Phase PHASE1
NCT05631574 Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Status TERMINATED Phase PHASE1
NCT05382377 NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors Status RECRUITING Phase EARLY_PHASE1
NCT05314309 Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening Status UNKNOWN Phase N/A
NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) Status COMPLETED Phase PHASE1/PHASE2
NCT05239650 Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC Status NOT_YET_RECRUITING Phase PHASE2
NCT05233332 Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) Status UNKNOWN Phase PHASE2
NCT05167071 HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05002270 JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Status COMPLETED Phase PHASE1/PHASE2
NCT04984369 The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment Status UNKNOWN Phase PHASE2
NCT04981119 Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Status RECRUITING Phase N/A
NCT04868773 Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy Status COMPLETED Phase PHASE1
NCT04808362 Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours Status TERMINATED Phase PHASE1/PHASE2
NCT04585035 Study to Evaluate D-1553 in Subjects With Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03965845 A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT03922906 Evaluation of Bowel Cleansing Using the Pure-Vu System in Patients With History of Inadequate Bowel Preparation Status TERMINATED Phase NA